Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases... Show more
Korro Bio is a clinical-stage biopharmaceutical company developing a new class of genetic medicines based on editing RNA rather than DNA. Its proprietary platform, Oligonucleotide Promoted Editing of RNA (OPERA), co-opts an enzyme naturally present in cells—ADAR (Adenosine Deaminases Acting on RNA)—to make precise, transient, single-base corrections to messenger RNA (mRNA). This approach is designed to deliver the therapeutic benefit of genetic correction while preserving the tunability and safety advantages of working at the RNA level, where edits are reversible.
Over the medium term, Korro's competitive positioning rests on two pillars: first, a differentiated "synthetic rescue" strategy for ammonia-driven diseases that could treat patients regardless of their underlying mutation; and second, a GalNAc-conjugated delivery approach that enables convenient subcutaneous dosing and targeted liver delivery. The company's decision to advance KRRO-111 for AATD—alongside its earlier KRRO-110 candidate—reflects an evolving strategy aimed at maximizing protein-correction levels and tolerability. Because Korro is pre-revenue, its market positioning is evaluated primarily on scientific differentiation and pipeline optionality rather than current market share, making the durability of its platform science the key structural consideration.
Several near-term developments could meaningfully reshape investor expectations. The most important are clinical data readouts for KRRO-121, which targets hyperammonemia in urea cycle disorders (UCD) and hepatic encephalopathy (HE), and for the AATD program. Korro has stated it is well-capitalized to report clinical data from both programs, positioning these results as pivotal value-inflection points.
The nomination of development candidates—including the May 2026 selection of KRRO-111 for AATD—represents a tangible de-risking step, while regulatory filings, trial initiations, and additional data disclosures will guide the next phase of the story. Capital allocation also matters: the March 2026 private placement, led by new investor Venrock Healthcare Capital Partners, extended the cash runway into the second half of 2028 and signals institutional conviction.
On the analyst front, sentiment has become more constructive. William Blair upgraded Korro Bio from Market Perform to Outperform in February 2026, and Cantor Fitzgerald upgraded the stock from Neutral to Overweight in January 2026. The consensus average one-year price target has moved higher—recently revised to approximately $19.53, reflecting a double-digit percentage increase—though the range of individual targets remains wide, underscoring the binary, data-dependent nature of the investment case.
Korro operates within the genetic-medicines sector, where scientific progress, regulatory review, and financing conditions intersect. The broader industry tailwind is clear: RNA-based and oligonucleotide therapies are advancing rapidly, with established regulatory pathways providing a precedent for Korro's delivery and manufacturing approach. The company's pivot to GalNAc conjugation aligns it with a proven modality used by approved liver-directed therapies, potentially reducing development risk.
Macroeconomic conditions matter primarily through the financing channel. As a pre-revenue company, Korro depends on equity capital markets to fund multi-year clinical programs. Elevated interest rates and risk-off conditions can compress valuations and raise the cost of capital for clinical-stage biotechs, while improving liquidity tends to support financing and partnership activity. Inflation and healthcare cost dynamics are secondary, given that Korro's near-term value is tied to clinical outcomes rather than commercial revenue.
Tickeron's Trend Prediction Engine is an AI-powered forecasting tool that helps traders assess whether a stock, exchange-traded fund (ETF), or other asset may trend bullish, bearish, or sideways over the next week or month. It is designed to help users identify developing trends, evaluate possible breakouts or reversals, and explore predictions across a broad range of tradable instruments. The product includes searchable prediction categories, historical context, and alert-oriented functionality to support timely decision-making. For investors seeking a data-driven complement to fundamental analysis, the Trend Prediction Engine offers a structured way to monitor short- to medium-term directional signals.
Looking toward 2026 and beyond, Korro's trajectory will be defined by whether its RNA-editing platform can convert preclinical promise into repeatable clinical proof. Long-term structural drivers include the potential to expand beyond rare diseases into more prevalent indications—exemplified by its interest in longevity and liver-health programs targeting the AMPK (AMP-activated protein kinase) pathway—and the scalability of its oligonucleotide-based manufacturing.
Cost structure and margin sustainability are secondary for a pre-revenue company, but the efficiency of the OPERA platform and the convenience of infrequent subcutaneous dosing could, if validated, support an attractive commercial profile. Competitive threats are real: Korro faces rival RNA-editing and gene-therapy developers targeting the same AATD and hyperammonemia populations, and differentiation will hinge on editing efficiency and safety data.
Capital allocation priorities will remain focused on clinical execution and pipeline advancement, with the extended cash runway into late 2028 providing strategic flexibility. Regulatory developments—including the FDA's (U.S. Food and Drug Administration) posture toward RNA-editing therapies—will be a key swing factor. Consensus analyst expectations remain constructive but wide-ranging, reflecting genuine uncertainty about trial outcomes. Investors should weigh these catalysts against the inherent risks of a clinical-stage, pre-revenue biotech.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| RHTX | 18.74 | N/A | N/A |
| RH Tactical Outlook ETF (RHTX) | |||
| FCTR | 31.56 | -0.18 | -0.56% |
| First Trust Lunt U.S. Factor Rotation ETF (FCTR) | |||
| FBL | 22.19 | -0.19 | -0.85% |
| GraniteShares 2x Long META Daily ETF (FBL) | |||
| EAGL | 34.53 | -0.45 | -1.29% |
| Eagle Capital Select Equity ETF (EAGL) | |||
| SLVR | 39.63 | -1.96 | -4.72% |
| Sprott Silver Miners & Physical Silver ETF (SLVR) | |||
A.I.dvisor indicates that over the last year, KRRO has been loosely correlated with EDIT. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if KRRO jumps, then EDIT could also see price increases.
| Ticker / NAME | Correlation To KRRO | 1D Price Change % | ||
|---|---|---|---|---|
| KRRO | 100% | +0.97% | ||
| EDIT - KRRO | 49% Loosely correlated | -3.01% | ||
| RCKT - KRRO | 46% Loosely correlated | N/A | ||
| MGNX - KRRO | 45% Loosely correlated | -3.90% | ||
| TRDA - KRRO | 43% Loosely correlated | +1.41% | ||
| DNLI - KRRO | 39% Loosely correlated | +2.22% | ||
More | ||||
Industry Biotechnology
The 10-day RSI Oscillator for KRRO moved out of overbought territory on November 05, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 28 instances where the indicator moved out of the overbought zone. In 27 of the 28 cases the stock moved lower in the days that followed. This puts the odds of a move down at 90%.
The Momentum Indicator moved below the 0 level on November 13, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on KRRO as a result. In 71 of 81 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 88%.
The Moving Average Convergence Divergence Histogram (MACD) for KRRO turned negative on November 13, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 42 similar instances when the indicator turned negative. In 36 of the 42 cases the stock turned lower in the days that followed. This puts the odds of success at 86%.
The 50-day moving average for KRRO moved below the 200-day moving average on October 15, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where KRRO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
KRRO moved above its 50-day moving average on October 22, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for KRRO crossed bullishly above the 50-day moving average on October 30, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 14 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.
Following a +6.64% 3-day Advance, the price is estimated to grow further. Considering data from situations where KRRO advanced for three days, in 227 of 263 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
KRRO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 110 of 127 cases where KRRO Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 87%.
The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. KRRO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 64 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.104) is normal, around the industry mean (3.592). P/E Ratio (-1.493) is within average values for comparable stocks, (-1.190). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.305) among similar stocks. P/S Ratio (69.444) is also within normal values, averaging (442.120).
The Tickeron PE Growth Rating for this company is 80 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. KRRO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.